What does the exosome market actually look like?

Independent quality comparison and pricing benchmarks for biologic products. Suppliers are anonymized. Methodology is published. Data is verifiable. This is what we found.

⚠ This site does not promote, sell, or facilitate the purchase of any product. It publishes market data only. No therapeutic claims. No medical advice. No FDA-approved exosome products exist as of July 2026.

01 — Quality Comparison

Metric	Supplier A	Supplier B	Supplier C
Form Factor	Lyophilized Freeze-dried powder · 2yr shelf life at -86°C	Cryopreserved Liquid frozen · -80°C/18mo, -20°C/6mo, 4°C/3mo	Fresh/Frozen Non-lyophilized · Room temp 24hr, freezer 6wk, cryo 18mo
COA Issuer	✓ VRL Eurofins Independent · CLIA-certified · USP <71> & <85>	✓ RayBiotech + IDEXX + Alpha Nano Tech Multiple independent labs · 30+ pathogen panel	✗ Unknown No COA located in distributor records
CD9/CD63/CD81 Markers	✗ Not available Requested Jul 2026 · Supplier did not respond	✓ RayBiotech flow cytometry CD9 & CD81 positive · CD63 near background (noted as acceptable per ISEV)	✗ Not available No characterization data provided
NTA Particle Count	✓ Verified 1.0×10⁹–10¹² particles/mL · 50–250nm range	✓ Alpha Nano Tech 1.30×10¹² particles/mL · Mean 124.6nm · DLS data included	✗ Not verified No NTA documentation in distributor records
Sterility Testing	✓ USP <71> · 14-day VRL Eurofins · 10% lot sample	✓ IDEXX BioAnalytics 30+ pathogen PCR · Aerobic/anaerobic/fungal · All negative	✗ Unknown No sterility documentation provided
Endotoxin	✓ USP <85> VRL Eurofins	✓ 0.011 EU/mL RayBiotech · Threshold: 0.1 EU/mL · Well below limit	✗ Unknown No endotoxin data
Donor Screening	✓ 21 CFR 1271 11 infectious disease tests · HIV, Hep B/C, CMV, Zika, SARS-CoV-2	✓ Full panel Hep B/C, HIV-1/2, HTLV I/II, Syphilis, CMV, Chagas, WNV · All negative	~ Unknown No donor screening documentation in records
Growth Factor Panel	✓ 234 proteins RayBiotech cytokine array · 80 cytokines	~ Included in product docs Secretome profile documented per tissue source	✗ External analysis only Third-party protein analysis of different product line
Facility Standard	cGMP · FDA-registered 21 CFR 1271 HCT/P establishment	✓ cGMP · 7 source labs Multiple FDA-registered facilities	✗ Unknown Facility credentials not documented
MLR / Bioactivity Data	✓ MLR assay Shows downregulation of inflammatory cytokines	~ Product-specific Bioactivity varies by tissue source and formulation	✗ None No bioactivity or functional assay data

02 — Pricing Benchmarks

Market Reference — Patient Price

$3,500–$8,000

Per IV session · Patient-facing · Source: StemConnect 2026

Market Reference — Research Wholesale

$980–$1,324

Per billion particles · Research-grade · Source: Zen-Bio 2026

Standard Distributor Markup

20–40%

Specialty/medical distributors · Source: Conga, Vendavo, MedPAC

Cost Metric	Supplier A	Supplier B	Supplier C
Primary Product	Matrix Exosome 1mL ~1,000 billion particles · Lyophilized	ProdigyXO 1mL ~350 billion particles · Cryopreserved	MSC Exosome 5mL ~100 billion particles · Fresh/Frozen
Wholesale Cost	$400	$400	$3,500
Cost per Billion Particles	$0.40 / billion	$1.14 / billion	$35.00 / billion
Particle Count Spread	$0.40 · Supplier A · $1.14 · Supplier B · $35.00 · Supplier C — 87.5× spread from lowest to highest
Volume Discounts	✓ 10–15% 10+ units: 10% off · 15+ units: 15% off	~ TBD Partnership terms pending · Some products fixed-price	✗ Unknown No volume tier documentation
Product Range	4 SKUs Exosome · Stem cell · Nasal spray · Eye drops	35+ SKUs Exosomes · MSCs · MUSE cells · Growth factors · Tissue-specific	~6 SKUs Injectable · Nebulizer · Topical gels

03 — Methodology

Data Sources

Pricing and quality data sourced from Certificates of Analysis (COAs), wholesale price lists, distributor agreements, and direct supplier communications. All documents obtained from active distribution relationships. Suppliers anonymized to protect commercial relationships while maintaining data verifiability.

Cost Normalization

All pricing is normalized to cost per billion exosome particles. This is the only metric that enables cross-supplier comparison, as products vary widely in concentration, volume, and form factor. Raw per-vial pricing is misleading without particle count.

Quality Scoring

Metrics based on MISEV guidelines, ISEV standards, 21 CFR 1271 requirements, USP <71> (sterility) and USP <85> (endotoxin). Independent lab verification weighted higher than in-house testing. CD9/CD63/CD81 marker presence required for full characterization under ISEV guidelines.

Limitations

Sample size: 3 suppliers. Data reflects wholesale pricing at a single point in time (July 2026). Does not include shipping, customs, or cold-chain logistics costs. Quality data limited to documentation provided by suppliers. Historical pricing trends not yet available.

Market References

Patient pricing sourced from published clinic pricing and industry surveys (StemConnect 2026). Research wholesale pricing from published academic procurement data (Zen-Bio 2026). Distributor markup norms from industry benchmarks (Conga, Vendavo, MedPAC).

Updates

This is v0.1.0. Data will be refreshed as new COAs, price lists, and supplier documentation become available. Methodology refinements and additional suppliers planned for future releases. Contact below for submissions or corrections.

04 — What This Is (And Isn't)

This is: An independent attempt to measure what the exosome market actually looks like — what products cost per unit of active ingredient, what quality documentation exists, and how suppliers compare on objective, verifiable metrics. The regenerative medicine industry suffers from severe information asymmetry. This is one small step toward transparency.

This is not: A marketplace. A recommendation engine. Medical advice. An endorsement of any supplier or product. A promotional vehicle. It publishes data. Nothing more.

The premise: A market where one supplier's product costs 87.5× more per unit than another's — and no public source documents this — is a market that needs measurement. We're measuring.